Research Article, J Vet Sci Med Diagn Vol: 4 Issue: 4
Primary Glaucoma and Long- Term Topical Application of 0.005% Latanoprost Effects on Intraocular Pressure in Uncontrollable used Multidrug Medications or Single used in Dogs
Kato K1* and van der Woerdt A2 |
1Kumi Animal Hospital, Ophthalmology, Saitama-ken, Japan |
2The Animal Medical Center, New York, USA |
Corresponding author : K Kato Kumi Animal Hospital, Ophthalmology 3-47-1 Cyuo, Misato-shi, Saitama-ken 341-0034, Japan Tel: +81 48 953 7755; Fax: +81 48 952 3893 E-mail: 55kumi.k@gmail.com |
Received: August 26, 2015 Accepted: September 27, 2015 Published: October 05, 2015 |
Citation: Kato K, van der Woerdt A (2015) Primary Glaucoma and Long-Term Topical Application of 0.005% Latanoprost Effects on Intraocular Pressure in Uncontrollable used Multidrug Medications or Single used in Dogs. J Vet Sci Med Diagn 4:4. doi:10.4172/2325-9590.1000171 |
Abstract
Primary Glaucoma and Long- Term Topical Application of 0.005% Latanoprost Effects on Intraocular Pressure in Uncontrollable used Multidrug Medications or Single used in Dogs
Objective: To evaluate the effect of long-term topical application of 0.005% latanoprost on intraocular pressure (IOP) in dogs with primary glaucoma Animal studied: One hundred-and-five dogs with primary glaucoma. Procedure: Latanaprost was used and/or added to existing medications for a minimum of 2 months. The iridocorneal angle (ICA) was measured and graded as open, slightly narrow, narrow, or closed. Baseline IOP was established at the time of the decision to initiate latanoprost treatment. Dogs were classified as responders if the IOP decreased with treatment or as non-responders if there was no decrease in the IOP. Results: The IOP did not decrease in 14 dogs (13.3%), and decreased initially, but increased again over time in 45 dogs (42.9%). The IOP was maintained at low levels in 46 dogs. There was no correlation between ICA grade and IOP reduction from baseline. Conclusions: Topical application of 0.005% latanoprost controlled IOP long-term in 43.8% of dogs with primary glaucoma. The remaining dogs had either no response to this treatment, or showed a temporary decrease in IOP.